Last updated: October 30, 2026
Zemaira is CSL Behring’s plasma-derived alpha1-proteinase inhibitor, also called alpha1-antitrypsin or A1PI. The FDA approved Zemaira in 2003 for chronic augmentation therapy in adults with severe alpha1-antitrypsin deficiency and emphysema. Its commercial position is supported by a specialized patient population, recurring weekly intravenous dosing, limited manufacturer capacity, and high barriers to biologic manufacturing. Its main risks are payer scrutiny, competing A1PI products, subcutaneous alternatives in development, and the absence of publicly disclosed brand-level revenue data. [1]
What is Zemaira and how does it generate revenue?
Zemaira replaces deficient alpha1-proteinase inhibitor in patients with severe congenital alpha1-antitrypsin deficiency. The product is administered by intravenous infusion, generally at 60 mg/kg once weekly. Treatment is chronic and usually continues for as long as the patient remains an appropriate candidate for augmentation therapy. [1]
| Attribute |
Zemaira |
| Active ingredient |
Alpha1-proteinase inhibitor, human |
| Product type |
Plasma-derived biologic |
| Manufacturer |
CSL Behring |
| FDA approval |
2003 |
| US application |
BLA 125285 |
| Administration |
Intravenous infusion |
| Standard dosing |
60 mg/kg weekly |
| Primary population |
Adults with severe A1PI deficiency and emphysema |
| Commercial model |
Chronic specialty therapy |
| Main competitors |
Prolastin-C, Glassia, Aralast NP |
Revenue depends on four variables: the number of diagnosed and treated patients, duration of therapy, reimbursement coverage, and the company’s ability to secure plasma and manufacturing capacity. Because treatment is weight-based, annual revenue per patient can be substantial and varies with body weight, net price, discounts, and site-of-care economics.
CSL Behring does not generally report Zemaira revenue as a separate public line item. Its financial disclosures group products into broader categories, including immunoglobulins and other plasma-derived therapies. As a result, public filings do not support a precise Zemaira sales figure or brand-specific compound annual growth rate. [2]
What is the financial trajectory for Zemaira?
Zemaira’s financial trajectory is likely mature rather than launch-driven. The product has been commercialized for more than two decades, so growth depends on market expansion, diagnosis rates, treatment penetration, price, and patient retention rather than rapid new-indication uptake.
Revenue drivers
The principal positive drivers are:
- Increased testing for alpha1-antitrypsin deficiency among patients with early-onset or unexplained emphysema.
- Greater physician awareness of augmentation therapy.
- Continued reimbursement for chronic treatment.
- Expansion of the diagnosed patient pool through family screening.
- Product switching within the A1PI category.
- Stable demand from patients already receiving weekly therapy.
The treated population remains smaller than the genetically affected population because alpha1-antitrypsin deficiency is substantially underdiagnosed. The Alpha-1 Foundation estimates that many affected individuals remain undiagnosed, although prevalence estimates vary by genotype and geography. [3]
Financial constraints
Zemaira faces several structural limits:
- The eligible population is narrow.
- Weekly intravenous administration limits convenience.
- Payers may restrict treatment to patients meeting genotype, serum-level, lung-function, and emphysema criteria.
- Plasma-derived supply is exposed to collection volumes, donor availability, manufacturing yields, and regulatory requirements.
- The clinical value proposition remains dependent on evidence concerning long-term outcomes, including emphysema progression and lung-density preservation.
CSL’s company-wide plasma collection and manufacturing scale is an advantage, but it also means that A1PI competes internally for plasma capacity with higher-volume products such as immunoglobulins and albumin. CSL has stated that plasma collection and fractionation capacity are central to its broader growth strategy. [2]
How large is the alpha1-proteinase inhibitor market?
The global A1PI augmentation market is a specialty biologics market with annual sales generally estimated by commercial analysts in the low-single-digit billions of dollars, depending on whether estimates include all A1PI products, geographies, and related diagnosis markets. Public company filings do not provide a consistent market-size methodology.
The United States is the largest commercial market because it has:
- A comparatively large diagnosed treatment population.
- Several approved products.
- Established specialty pharmacy and infusion channels.
- Reimbursement pathways for chronic augmentation therapy.
- Higher net pricing than most international markets.
Europe is strategically important but more fragmented. Treatment access varies by country, and national reimbursement agencies may apply different eligibility and cost-effectiveness standards.
Zemaira competes in a concentrated market. Product selection can depend on supply, infusion provider relationships, hospital contracts, specialty pharmacy distribution, patient support, and physician familiarity. Therapeutic interchangeability is not automatic because these are biologic products with different manufacturing processes and labeling histories.
Which companies compete with Zemaira?
Prolastin-C
Prolastin-C is marketed by Grifols and is one of the best-established A1PI products. Grifols has a large plasma collection and fractionation network, giving it a direct supply-chain position in the category. Prolastin-C is also available in an injectable formulation designed for intravenous administration. [4]
Glassia
Glassia is marketed in the United States by Takeda after Shire’s acquisition by Takeda. Glassia is a liquid alpha1-proteinase inhibitor product administered intravenously. Takeda’s global plasma-derived portfolio and manufacturing infrastructure support its competitive position. [5]
Aralast NP
Aralast NP is another intravenous alpha1-proteinase inhibitor. Its commercial role is smaller than the two largest branded competitors in many markets, but it remains relevant in contracting, supply, and product availability decisions. [6]
| Product |
Company |
Product class |
Primary competitive factor |
| Zemaira |
CSL Behring |
Plasma-derived A1PI |
CSL plasma scale, brand presence, supply |
| Prolastin-C |
Grifols |
Plasma-derived A1PI |
Established franchise and plasma network |
| Glassia |
Takeda |
Plasma-derived A1PI |
Liquid formulation and Takeda infrastructure |
| Aralast NP |
Takeda-related commercial portfolio |
Plasma-derived A1PI |
Additional supply option |
The market is therefore more concentrated than a typical small-molecule generic market. Competitors are established biologics manufacturers rather than low-cost generic entrants.
What FDA regulatory status does Zemaira have?
Zemaira is FDA-approved under BLA 125285 for chronic augmentation and maintenance therapy in adults with alpha1-antitrypsin deficiency and emphysema. The label states that clinical benefit on pulmonary exacerbations and progression of emphysema has not been established in controlled clinical trials. The approval is based on biochemical augmentation and related evidence rather than a definitive demonstration of every long-term clinical outcome. [1]
This distinction matters commercially. Physicians and payers may support therapy based on guideline recommendations, biological plausibility, registry data, and available clinical evidence, but reimbursement policies can differ over the level of evidence required.
The product is not a conventional small-molecule drug listed in the Orange Book for Hatch-Waxman patent certification. Biologic exclusivity and biosimilar competition are assessed through the Public Health Service Act framework and the FDA Purple Book. [7]
What patents protect Zemaira?
Zemaira’s current commercial protection is more likely to depend on biologic manufacturing know-how, regulatory exclusivity history, trademarks, supply infrastructure, and market relationships than on a single active patent blocking generic entry.
The product was approved in 2003. Any original US regulatory exclusivity has expired. Patents covering the original product, purification methods, plasma processing, formulations, or manufacturing processes may have expired, been abandoned, or remain relevant only in particular jurisdictions. A complete live patent determination requires a current review of US and foreign patent registers, assignment records, terminal disclaimers, maintenance fees, and claim scope.
Manufacturing and trade-secret barriers
The main practical barriers are:
- Plasma donor recruitment and collection.
- Viral inactivation and pathogen-removal controls.
- Fractionation and purification yield.
- Batch consistency.
- Release testing.
- Regulatory comparability.
- Long-term supply reliability.
- Specialized distribution and infusion support.
These barriers can delay competition even when no broad blocking patent remains. A competitor must establish a licensed biologic manufacturing process and demonstrate sufficient similarity or safety and efficacy under the applicable regulatory pathway.
When does Zemaira lose exclusivity?
Zemaira’s original FDA approval occurred in 2003, so the standard 12-year reference-product exclusivity period for a biologic has elapsed. The product does not have a forthcoming basic loss-of-exclusivity date comparable to a small molecule approved in the last decade.
Patent expiration is a separate issue. No single, publicly established patent expiration date can be assigned to the Zemaira brand without a current claim-by-claim review of relevant patents and patent families. The practical entry question is whether an applicant can obtain approval for a competing A1PI product, not simply whether an old Zemaira patent has expired.
Are there Paragraph IV challenges or biosimilar risks for Zemaira?
Paragraph IV litigation
Paragraph IV certifications apply principally to abbreviated new drug applications under the Hatch-Waxman Act. Zemaira is a biologic licensed under a BLA, so a conventional Paragraph IV challenge is not the primary expected route to competition.
A competitor would generally pursue a biosimilar or interchangeable-biologic pathway under the Public Health Service Act. The FDA Purple Book identifies licensed biological products and biosimilar relationships. [7]
Biosimilar risk
As of June 2024, Zemaira did not face an FDA-approved biosimilar competitor listed as interchangeable with the product. The absence of a biosimilar does not eliminate future risk. A future applicant would need to address:
- Analytical similarity to the reference product.
- Clinical pharmacology and immunogenicity.
- Product-specific manufacturing complexity.
- Reference-product sourcing and regulatory strategy.
- Market access and infusion economics.
Biosimilar development may be slower than development for simpler recombinant proteins because plasma-derived A1PI has complex source material and process attributes. That complexity raises development costs and increases the importance of manufacturing comparability.
What formulations are protected by Zemaira’s commercial position?
Zemaira is an intravenous, plasma-derived product supplied for reconstitution and infusion. Its commercial differentiation is not based on an orally administered formulation or a long-acting delivery system.
The greatest formulation threat would come from a subcutaneous or otherwise less burdensome A1PI therapy. A successful subcutaneous product could reduce infusion-center use, improve patient convenience, and change payer comparisons. The threat would depend on adequate systemic exposure, sustained serum levels, immunogenicity, safety, adherence, and proof that convenience translates into better persistence.
The development of inhaled or engineered A1PI products could also pressure the intravenous category, although regulatory and clinical requirements remain substantial.
What patent litigation and settlement agreements affect Zemaira?
No major publicly established patent settlement involving Zemaira and a biosimilar entrant had created a defined US generic-entry date as of June 2024. The principal litigation risk is therefore not a known imminent Paragraph IV launch but future disputes over biosimilarity, manufacturing patents, process claims, regulatory interchangeability, and market conduct.
Because A1PI products are biologics, litigation may involve the Biologics Price Competition and Innovation Act patent-information exchange process rather than a standard Orange Book certification dispute. Any future case would need to be evaluated through FDA filings, federal court dockets, and the parties’ patent disclosures.
How strong is the Zemaira patent estate?
The Zemaira patent estate appears commercially moderate when assessed solely on traditional product-patent exclusivity. The product’s approval date means that original regulatory exclusivity has expired, and a mature biologic cannot rely indefinitely on early composition patents.
The broader competitive moat is stronger because it includes:
- Plasma supply scale.
- Manufacturing experience.
- Quality systems.
- Established reimbursement pathways.
- Physician familiarity.
- Patient-service infrastructure.
- Switching friction in chronic infusion therapy.
This is a supply-chain and execution moat rather than a clearly identifiable long-dated patent moat.
What generic or biosimilar launch scenarios exist for Zemaira?
| Scenario |
Timing profile |
Commercial effect |
| No near-term biosimilar |
Most likely short-term outcome |
Zemaira retains pricing and share stability |
| Limited biosimilar entry |
Medium-term possibility |
Contracting pressure and selective switching |
| Multiple biosimilars |
Lower-probability medium- to long-term scenario |
Net price erosion and payer-driven substitution |
| Subcutaneous competitor |
Product-dependent |
Infusion displacement and convenience-based switching |
| Plasma supply disruption |
Episodic risk |
Temporary shortages and allocation changes |
A first biosimilar would probably target contracts and payer coverage before causing rapid universal substitution. Physicians may remain conservative because patients receive chronic therapy and products are not necessarily treated as interchangeable without a formal designation.
How does Zemaira compare with Prolastin-C and Glassia?
Zemaira, Prolastin-C, and Glassia address the same underlying deficiency but compete through different corporate platforms.
| Factor |
Zemaira |
Prolastin-C |
Glassia |
| Parent company |
CSL Behring |
Grifols |
Takeda |
| Plasma scale |
Very large |
Very large |
Large |
| Commercial maturity |
Mature |
Mature |
Mature |
| Key advantage |
CSL infrastructure and supply |
A1PI specialization and plasma network |
Takeda portfolio and liquid product |
| Main weakness |
IV burden and category pricing |
Same category-wide constraints |
Same category-wide constraints |
| Biosimilar exposure |
Future risk |
Future risk |
Future risk |
No product has an uncontested clinical or delivery advantage sufficient to eliminate the others. Supply reliability, payer contracts, patient support, and infusion logistics can determine share more directly than modest formulation differences.
What is the commercial outlook for Zemaira?
Zemaira should remain a durable specialty biologic with relatively predictable recurring demand. The most likely financial path is low-to-moderate underlying growth, offset by pricing pressure and competition within a concentrated market.
Upside depends on improved diagnosis and treatment penetration. Downside depends on payer restrictions, supply disruptions, evidence-based reimbursement challenges, and a more convenient A1PI delivery system.
The brand’s value is tied less to patent-protected exclusivity than to CSL Behring’s integrated plasma platform. That platform supports continued commercial durability, but it also limits the probability of high-growth expansion absent a major increase in diagnosis or a meaningful new indication.
Key Takeaways
- Zemaira is a mature CSL Behring biologic approved in 2003 for chronic intravenous augmentation therapy.
- CSL does not publicly disclose brand-level Zemaira revenue, so a precise financial trajectory cannot be verified from public filings.
- The US A1PI market is concentrated among Zemaira, Prolastin-C, Glassia, and Aralast NP.
- Original biologic exclusivity has expired, and conventional Paragraph IV litigation is not the primary competitive pathway.
- No FDA-approved biosimilar to Zemaira was listed as of June 2024.
- The principal commercial moat is plasma supply, manufacturing capability, quality systems, and distribution rather than a clearly identifiable long-dated product patent.
- The largest strategic threat is a clinically effective subcutaneous or other convenient A1PI delivery system.
- Near-term Zemaira revenue is likely to remain stable, with growth tied to diagnosis and treatment penetration rather than new-product exclusivity.
FAQs about Zemaira market and patent risk
Is Zemaira a biologic or a generic drug?
Zemaira is a plasma-derived biologic. It is not a conventional small-molecule drug subject to standard generic substitution through an abbreviated new drug application.
Does Zemaira have Orange Book patents?
The relevant regulatory framework is generally the biologics framework and the FDA Purple Book rather than the conventional Orange Book patent-listing system used for small-molecule products.
Who manufactures Zemaira?
CSL Behring manufactures and markets Zemaira. CSL Behring is part of CSL Limited, a global plasma-products company.
Can patients switch between Zemaira and Prolastin-C?
Switching may be clinically possible, but it should be managed by the treating physician. Payer policies, product availability, infusion logistics, and patient-specific factors affect the decision.
What would most reduce Zemaira sales?
The most material threats are a competing subcutaneous A1PI product, a clinically accepted biosimilar with strong payer support, sustained reimbursement restrictions, or a significant disruption in plasma-derived product supply.
References
- U.S. Food and Drug Administration. (2023). Zemaira: Prescribing information, BLA 125285.
- CSL Limited. (2023). Annual report 2023.
- Alpha-1 Foundation. (2024). Alpha-1 antitrypsin deficiency: Disease overview and diagnosis.
- Grifols, S.A. (2023). Prolastin-C prescribing information.
- Takeda Pharmaceuticals U.S.A., Inc. (2023). Glassia prescribing information.
- U.S. Food and Drug Administration. (2023). Aralast NP prescribing information.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
